PainCast

Tag: chronic pain

  • Pharmacological Advances in Opioid Therapy: The Role of Oliceridine in Pain Management

    Pharmacological Advances in Opioid Therapy: The Role of Oliceridine in Pain Management

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on November 2, 2021

    Dr. Alex D. Pham discusses pharmacological advances in opioid therapy and the role of oliceridine. As the number of patients with pain has grown, so has the need for better pharmacological treatments. Oliceridine provides a compelling alternative because this compound that binds to mu-opioid receptors but are coupled to a Beta-arrestin inhibitor. This allows for analgesia with a reduced side effect profile. Overall, a literature analysis supports the use of oliceridine for pain management.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • DRG and Chronic Pain

    DRG and Chronic Pain

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on October 11, 2021

    Dr. Alex D. Pham discusses the dorsal root ganglion (DRG) and chronic pain. Chronic neuropathic pain is widespread and difficult to treat. However, targeting the DRG has begun to show promising effects in pain alleviation. Dr. Pham and his colleagues conducted a systemic literature search and found several promising case reports that support the use of DRG stimulation. Overall, this developing technique may allow for a precise approach to chronic pain management.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • Cervicogenic Headaches

    Cervicogenic Headaches

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on April 2, 2021

    Dr. Miles Day discusses cervicogenic headaches at the 24th Annual Gabor Racz Pain Conference and Workshop. He describes the history of this type of headache, as well as diagnostic criteria and potential pain generators. He also explains how proper clinical examinations are important in the diagnosis and proper treatment of these headaches.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • The Basis of Neuropathic Pain

    The Basis of Neuropathic Pain

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on March 19, 2021

    Where does neuropathic pain come from? This type of pain is a complex phenomenon that remains little understood. Here, renowned pain researcher Marshall Devor, PhD, describes the biological mechanisms of neuropathic pain and explains why some pain therapies succeed or fail. Prof. Devor also discusses why studying unconsciousness helps us better understand pain.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • What Can Military Medicine Teach Us

    What Can Military Medicine Teach Us

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on January 8, 2021

    Dr. Scott Griffith talks about what pain physicians can learn from military medicine. He begins with a recent history of military contributions to pain medicine and highlights key technological advances. He discusses acute and chronic pain treatment in theater and the role of the Army Pain Task Force. He also addresses concerns about opioid use and steps the military is taking to address them.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • COVID-19 & Chronic Pain

    COVID-19 & Chronic Pain

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on September 28, 2020

    One in five individuals develop chronic pain over a period of time . How do we deal with this new group of individuals who are going to suddenly arrive into pain clinics going forward? Join Dr. Dominic Hegarty, MD for A brief discussion of COVID-19 and the implications going forward from a rehabilitation perspective and what we might try and expect for patients who have chronic pain already and for those individuals who may develop new pain.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • ASPN Virtual Think Tank – Session 3: Targeted Drug Delivery and SI Fusion

    ASPN Virtual Think Tank – Session 3: Targeted Drug Delivery and SI Fusion

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on August 25, 2020

    Hosted by Tim Deer, MD, and Dawood Sayed, MD, the purpose of this Think Tank is to have an open discussion between clinicians, scientists, administrators and industry to advance the field of interventional pain management. A Flowonix panel begins this discussion led by Jason Pope, MD on the future of intrathecal drug delivery and intrathecal dosing. CornerLoc is next, presented by Steven Falkowski, MD, and Denis G. Patterson, DO to share thoughts on stabilization and bone healing in SI joint arthrodesis. PainTEQ completes the evening with Drs. Youseff Josephson, Steven Falowski, Kasra Amirdelfan, and Jeffrey S. Henn discussing new innovations in minimally invasive SI fusion.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • ASPN Virtual Think Tank – Session 2: Spinal Cord Stimulation Pt. 2

    ASPN Virtual Think Tank – Session 2: Spinal Cord Stimulation Pt. 2

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on August 25, 2020

    Hosted by Tim Deer, MD, and Dawood Sayed, MD, the purpose of this Think Tank is to have an open discussion between clinicians, scientists, administrators and industry to advance the field of interventional pain management. On behalf of Nevro. new indications and advancements with 10kH SCS is discussed by Kasra Amirdelfan, MD, Jordan Lee Tate, MD, MPH, and John Goree, MD. Boston Scientific joins the discussion by redefining personalization in pain management and expanding treatment options, led by Lou Raso, MD, Jennifer Lee, MD and Marshall Bedder, MD. Next, Peter Staats, MD, MBA, Sean Li, MD and Marc Russo, MD present the Saluda Medical panel: Delivering the Right Activation with Closed Loop SCS. Soin Neuroscience, Amol Soin, MD shares AI & Machine learning to facilitate precision medicine in spinal disorders. The session is rounded out by NeuraLace Medical’s discussion on Axon therapy, by Shiv Shukla, CEO.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • ASPN Virtual Think Tank – Session 1: Spinal Cord Stimulation

    ASPN Virtual Think Tank – Session 1: Spinal Cord Stimulation

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on August 25, 2020

    Hosted by Tim Deer, MD, and Dawood Sayed, MD, the purpose of this Think Tank is to have an open discussion between clinicians, scientists, administrators and industry to advance the field of interventional pain management. Keith Boettiger, President of Neuromodulation for Abbott begins the discussion with the global pandemic and its impact on chronic pain. Next, Medtronic Faculty of Krishnan Chakravarthy, MD, Michael Fishman, MD, MBA, Prabhdeep Grewal, MD and Ricardo Vallejo MD, PhD is assembled to discuss what you need to know about DTM™ (Differential Target Multiplexed) SCS. The session continues with Dr. Mark Malinowski, and Dr Sai Arulkumar on behalf of Nalu discussing expanding the patient population in SCS with a novel, battery-free, Micro-IPG. Dr. Erika Petersen closes the session with the poster to podium program exclusively from ASPN.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • Let’s Get Personal: Using Genetic and Environmental Factors to Guide Pain Treatment

    Let’s Get Personal: Using Genetic and Environmental Factors to Guide Pain Treatment

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on August 20, 2020

    Dr. Roger Fillingim discusses the value of a comprehensive approach to personalized medicine. After discussing the value of CYP2D6 genotyping to predict opioid efficiency, he shows that drug interactions drive CYP2D6 phenoconversion in some patients, proving that a purely genomic approach to precision medicine is insufficient. Using published data, he broadens the scope of personalized medicine to include non-genetic factors based on his biopsychosocial model of pain.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]